ESMO Events 2025

Meetings | ESMO

Welcome to our ESMO Virtual Congress site where we showcase the very best from ESMO's flagship portfolio.

ESMO Immuno-Oncology Annual Congress 2025

This international event provides valuable knowledge: from basic science to translational research and clinical development, cutting-edge science, and excellent networking opportunities.

Take part in this meeting to learn, share your research and expertise and connect with the stakeholders that are making a difference in the field.

Below a collection of papers recently published in ESMO’s premier journals carefully selected to reflect the themes of the meeting.

Annals of Oncology

• Emerging Options and Future Strategies in Immunotherapy for Advanced Lung Squamous Cell Carcinoma Y. Wang, R. Rosell, F.R. Hirsch, S. Lu, R. Govindan, K. Park, S. Peters, J.J. Zhang

• Early Positron Emission Tomography Response-Adapted Treatment in Low-Risk Diffuse Large B-Cell lymphoma: an open label, multicenter, randomised, non-inferiority phase 3 trial.

  Jean-Marie Michot, Serge Bologna, Jean-Noël Bastie, Thierry Vander Borght, Josette Brière, Vincent Ribrag, Come Bommier, Frédéric Peyrade, Laure Lebras, Gandhi Damaj, Diane Coso, David Sibon, Christophe Bonnet, Franck Morschhauser, Hervé Ghesquières, Christophe Fruchart, Carole Soussain, Stéphanie Becker, Pierre Olivier, Anne Julian, Thierry Molina, Corinne Haioun, Hervé Tilly

ESMO Open

• MOVIE phase II trial of tremelimumab plus durvalumab combined with metronomic oral vinorelbine in patients with head and neck cancer E. Borcoman, A. Hervieu, C. Cropet, E. Coquan, J. Guigay, F. Rolland, M. Bernadach, E. Charafe, F. Legrand, E. Dassé, C. Le Tourneau, A. Gonçalves

• Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50% A. De Giglio, L. Zullo, A. Di Federico, M. Cani, M. Aldea, D. Soldato, F.G. Dall’Olio, F. Mantuano, F. Sperandi, V. Favorito, A. Sadowska, L.E.L. Hendriks, T. Gorria, L. Mezquita, F. Tabbò, S. Novello, F. Gelsomino, B. Besse, A. Ardizzoni

Immuno-Oncology and Technology

• Intratumoral microbiome is associated with the response to cancer immunotherapy in lung cancer patients with high PD-L1 expression F. Shoji, T. Kawabata, K. Kosai, T. Fujishita, R. Toyozawa, S. Shimamatsu, K. Ito, K. Taguchi, M. Yamaguchi

• Subtype-specific genetic drivers of immune evasion in breast cancer O. Menyhart, B. Győrffy

• Sites of metastases before systemic treatment influence progression patterns and survival in stage IV melanoma patients I.A. Vergara, S.N. Lo, I. Li, J.W. Conway, X. Fu, A.M. Menzies, M.S. Carlino, R.A. Scolyer, G.V. Long, I.P. da Silva

• Longitudinal ctDNA monitoring in patients with metastatic uveal melanoma undergoing isolated hepatic perfusion in combination with ipilimumab and nivolumab M. Kadefors, A. Nelson, E. Blomberg, A. Ståhlberg, L. Ny, R. Olofsson Bagge

ESMO Gastrointestinal Oncology

• Molecular classification of microsatellite-instable colorectal cancers reveals distinct predictors of immunotherapy response C. Lin, T. Luo, M. Wu, F. Li, L. Nunes, A. Mezheyeuski, K. Hammarström, A. Isaksson, I. Ljuslinder, M. Uhlén, R. Palmqvist, S. Zhu, B. Glimelius, K. Wu, T. Sjöblom

• New perspectives in biliary tract cancers T.O. Goetze, C. Roderburg, F.W. Friedrich, J. Trojan

ESMO Rare Cancers

• Sclerosing mucoepidermoid carcinoma with eosinophilia of the thyroid with molecular profiling and unusual immunoprofile: a case report D. Turberg, S. Leboulleux, N. Zouggari, V. Du Bois, M. Mavromati, M.S. Demarchi, F. Triponez, P.M. Sadow, C. De Vito

• Advances in alveolar soft part sarcoma treatment in the era of immunotherapy H. Suto

ESMO Real World Data and Digital Oncology

• Clinical evaluation of an automated pan-organ combined PD-L1 scoring using artificial intelligence on immunostained whole-slide images C. Bossard, C. Magois, H. Roussel, F. Thomas, B. Cormier, A. Collin, V. Lemerle, I. Chokri, L. Lambros, F. Jossic, J.-F. Jazeron, C. Eymerit-Morin, A. Dhouibi, N. Labaied, A. Mensah, B. Gourdin, F. Leclair, D. Pommeret, Y. Salhi, M. Cecchini, N. Rioux-Leclercq, J. Chetritt

• Integrating radiomics and real-world data to predict immune checkpoint inhibitor efficacy in advanced non-small-cell lung cancer☆ L. Provenzano, M. Favali, L. Mazzeo, A. Spagnoletti, M. Ruggirello, G. Calareso, F.G. Greco, R. Vigorito, A. Quarta, F. Calimeri, M. Monteleone, G. Baselli, E. De Momi, B. Guirges, A. Di Lello, A. Zec, A. Ferrarin, C. Giani, C. Silvestri, M. Occhipinti, M. Brambilla, R. Leporati, S. Manglaviti, C. Cavalli, G. Mazzoli, D. Miliziano, G. Di Liberti, B.M. Marino, S. Frasca, R. Di Mauro, A.D. Dumitrascu, T. Beninato, C. Proto, M. Ganzinelli, A. Vingiani, D. Lorenzini, C. Agosta, M. Borraccino, C. Bonalume, V. Bartolomeo, R. Romanò, P. Solli, A.R. Filippi, S. Sangaletti, M. Restelli, A. Marchianò, M.C. Garassino, F. de Braud, F. Trovò, A.L.G. Pedrocchi, G. Lo Russo, V. Miskovic, A. Prelaj

ESMO affiliated journals

• Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial – BREASTIMMUNE-03 Olivier Trédan, Delphine Loirat, Sylvie Chabaud, Philippe Toussaint, Thierry Petit, Frédéric Viret, Christelle Levy, Aurélien Robert, Julien Grenier, Laura Mansi, Jean-Philippe Spano, Anne Patsouris, Olfa Derbel, Christelle Jouannaud, Jean Marc Ferrero, Jean Sébastien Frenel, Yann Molin, Louis Doublet, Pierre-Etienne Heudel, Jean-Yves Pierga, Gwenaële Garin, David Pérol, Thomas Bachelot

• Development and validation of prognostic model based on distribution and density of CD3+ and CD8+ infiltrating lymphocytes in breast cancer: A multicenter cohort study Xu Zhang, Zheng Wang, Yiwei Tong, Xi Sun, Weiqi Gao, Xiaocun Fei, Yujie Tang, Juanying Zhu, Zhi'an Li, Kunwei Shen, Xiaosong Chen

• Precision oncology in gastric cancer: Shaping the future of personalized treatment Cristina Migliore, Elisabetta Fenocchio, Silvia Giordano, Simona Corso

• CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation Reza Elahi, Yassine Alami Idrissi, Anwaar Saeed

• KRAS G12C-associated immunotherapy benefit in NSCLC is substantially mediated by tobacco-induced tumor mutation burden, not allele-specific effects Meng Liu, Jeffrey P. Townsend

• Coordinated humoral and cellular immune responses to COVID-19 vaccination in non-small cell lung cancer patients treated with immune checkpoint inhibitors Anna Lundgren, Susannah Leach, Joanna Kaim, Nikita Dutta, Ying Li, Frida Nilsson, Ahmed Jawad, Mats Bemark, Magnus Gisslén, Andreas Hallqvist, Sukanya Raghavan

• Retreatment With Anti-CD38-Based Combinations in Multiple Myeloma in Real-Life: Results From the Emmy Cohort Study Alexis Talbot, Cyrille Hulin, Aurore Perrot, Margaret Macro, Karim Belhadj Merzoug, Mohamed Mohty, Arthur Bobin, Lionel Karlin, Salomon Manier, Laure Vincent, Abderrazak El Yamani, Wajed Abarah, Regis Kaphan, Thomas Chalopin, Daniel Ré, Adrienne de Labarthe, Olivier Fitoussi, Chanaz Lounis, Ronan Garlantezec, Olivier Decaux, on behalf of EMMY and the IFM group

• Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma Sarit E. Assouline, Amitkumar Mehta, Walter Hanel, Stéphane Doucet, Patrick B. Johnston, Alexey V. Danilov, Brenda W. Cooper, Aleksander Chudnovsky, Junyu Ding, Tao Long, Dina Stroopinsky, Deborah Berg, Lapo Alinari

ESMO's Journal Portfolio

While diverse in nature and in content, these journals offer ESMO members and the oncology community a highly visible platform to publish important scientific studies, and a highly credible source for educational updates. Elsevier is the proud publisher of Annals of Oncology, Immuno-Oncology and Technology (IOTECH), ESMO Open, ESMO Gastrointestinal Oncology, ESMO Real World Data and Digital Oncology, ESMO Rare Cancers, and ESMO Affiliated Journals The Breast, Lung Cancer, Cancer Treatment Reviews and Clinical Lymphoma Myeloma and Leukemia.